Evidence map›Paper›PMID 34032896›Full record

ReviewRheumatology international2021

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?

Bahar Özdemir, Abdulsamet Erden, Serdar Can Güven, Berkan Armagan, Hakan Apaydin, Özlem Karakas, Ahmet Gokhan Akdag, İhsan Ates, Orhan Kucuksahin, Ahmet Omma

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bahar ÖzdemirDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey. bharozdemir@gmail.com.ORCID http://orcid.org/0000-0003-4711-4921
Abdulsamet ErdenDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Serdar Can GüvenDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Berkan ArmaganDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Hakan ApaydinDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Özlem KarakasDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Ahmet Gokhan AkdagDivision of Intensive Care, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
İhsan AtesDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Orhan KucuksahinDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Yıldırım Beyazıt University, Ankara, Turkey.
Ahmet OmmaDivision of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, 06100, Turkey.
Memorial Ankara Hospital · TRAnkara Yıldırım Beyazıt University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) and eosinophilic granulomatosis with polyangiitis (EGPA) share similarities in clinical, imaging findings and may present with respiratory distress. Differentiating a new-onset EGPA from COVID-19 during the current pandemic is a diagnostic challenge, particularly if other EGPA symptoms are overlooked. Here in this study we reviewed the literature regarding EGPA patients with COVID-19 and patients who diagnosed with EGPA or suffered an EGPA flare mimicking COVID-19. We conducted a literature survey in PUBMED database using meshed keywords "COVID-19" and "EGPA", "COVID-19" and "eosinophilic granulomatosis with polyangiitis", "COVID-19" and "Churg Strauss Syndrome", to reveal previously reported cases involving EGPA patients who had COVID-19 infection, patients who suspected to have COVID-19 but eventually diagnosed with EGPA and patients with a known diagnosis of EGPA who suffered a flare but a COVID-19 infection was suspected initially. A total of 11 cases (6 literature cases, 5 cases from our clinic) were included in our study. Seven (63.6%) of the cases were defined as COVID-19 mimicker and 4 (36.4%) were EGPA with COVID-19. All of the cases in EGPA with COVID-19 group had a history of asthma. All of them had a positive PCR result and ground-glass opacities in thorax CT. In COVID-19 mimicker group, six (85.7%) patients had a history of asthma and other EGPA features that were observed were eosinophilia in 6 (85.7%). Our study provided clues regarding the EGPA/COVID-19 diagnostic challenge which may be useful in the current pandemic. Since none of the findings in COVID-19 are disease-specific, other conditions like EGPA should not be overlooked particularly in PCR negative patients and clinical, laboratory and imaging findings should be interpreted carefully. Furthermore, we did not observe poor outcomes in EGPA patients who had COVID-19.

Indexed as

AdultChurg-Strauss SyndromeCOVID-19Diagnosis, DifferentialFemaleHumansMaleMiddle AgedPredictive Value of TestsYoung AdultChurg strauss syndromeCoronavirus disease 2019Eosinophilic granulomatosis with polyangiitisSevere acute respiratory syndrome—coronavirus 2

Identifiers

PMID34032896
PMCPMC8146171
OpenAlexW3164275801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.